Chemical reprogramming of human glial cells into neurons for brain and spinal cord repair
Provided are methods and compositions from reprogramming human glial cells into human neurons. The reprogramming is achieved using combinations of compounds that can modify signaling via Transforming growth factor beta (TGF-β), Bone morphogenetic protein (BMP), glycogen synthase kinase 3 (GSK-3), and γ-secretase/Notch pathways. The reprogramming is demonstrated using groups of three or four compounds that are chosen from the group thiazovivin, LDN193189, SB431542, TTNPB, CHIR99021, DAPT, VPA, SAG, purmorphamine. Reprogramming is demonstrated using the group of LDN193189/CHIR99021/DAPT, the group of B431542/CHIR99021/DAPT, the group of LDN193189/DAPT/SB431542, the group of LDN193189/CHIR99021/SB431542, a three drug combination of SB431542/CHIR99021/DAPT. Reprogramming using functional analogs of the compounds is also provided, as are pharmaceutical formulations that contain the drug combinations.
1. A method for reprogramming human glial cells in the brain of an individual comprising contacting the human glial cells with compounds that collectively inhibit Transforming growth factor beta (TGF-β), Bone morphogenetic protein (BMP), glycogen synthase kinase 3 (GSK-3), and γ-secretase/Notch pathways in the glial cells, wherein the contacting comprises administering to the glial cells in the brain at least one of the following combinations of compounds: i) LDN193189/CHIR99021/N-[(3,5-Difluorophenyl)acetyl]-L-alanyl-2-phenyl]glycine-1,1-dimethylethyl ester (DAPT), ii) SB431542/CHIR99021/DAPT; iii) LDN193189/DAPT/SB431542, or iv)) LDN193189/CHIR99021/SB431542, wherein the administering of the compounds is cell and virus free, and wherein the administering is sufficient such that at least some of the glial cells are reprogrammed to become neurons.
2. A method for generating neurons in the brain of an individual comprising administering to the individual a combination of compounds comprising at least three compounds selected from the group consisting of LDN193189, SB431542, CHIR99021, and N-[(3,5-Difluorophenyl)acetyl]-L-alanyl-2-phenyl]glycine-1,1-dimethylethyl ester (DAPT), wherein the administering of the compounds is cell and virus free, and wherein the neurons are generated.
3. The method of claim 2 wherein the combination of compounds comprises each of LDN193189, SB431542, CHIR99021, and DAPT.
4. The method of claim 1 , wherein the combination of the compounds comprises each of LDN193189, SB431542, CHIR99021, and DAPT.